Phase I – Other

1,082 trials 243 recruiting

Filter these 1,082 trials by condition, country, sponsor and more.

Open in Search →

A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the blo… Ended

2024-513656-15-00 Alzheimer's Disease (Healthy Participants) 2022-10-17
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisin… Ended

2022-500954-40-00 Nicotine addiction 2022-10-17
Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended

2024-515196-35-00 Platinum-Resistant Ovarian Cance 2022-09-29
Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended

2022-500287-35-00 Metastatic or Locally Advanced Unresectable Solid Tumor 2022-09-21
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Pa… Ended

2023-504412-14-00 Early Idiopathic Parkinson’s Disease (PD) 2022-09-01
A study to learn how the study drug elinzanetant (BAY 3427080) affects the way the drug dabigatran moves into, through and out of the body i… Ended

2022-500201-41-00 Healthy volunteers (Vasomotor Symptoms as a sex hormone 2022-08-02
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone … Ended

2024-516661-37-00 Metastatic Prostate Cancer 2022-07-27
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Ended

2024-516743-34-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 2022-07-25
Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type gl… Ended

2024-514424-16-00 MGMT-Methylated, IDH wild-type glioblastoma 2022-07-04
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero… Ended

2022-502981-26-00 Systemic Sclerosis 2022-06-27
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C… Ended

2024-514532-24-00 Solid cancer tumors 2022-06-23
A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n… Ended

2024-512799-36-00 hepatocellular carcinoma 2022-06-16
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination… Ended

2024-511352-41-00 advanced solid tumors 2022-06-13
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo… Ended

2024-510644-31-00 Relapsed/Refractory Multiple Myeloma 2022-06-10
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and p… Ended

2024-516692-32-00 Refractory metastatic Her2 positive breast cancer 2022-05-26
This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B… Ended

2023-504795-20-00 Relapsed/Refractory Aggressive Mature B-cell Neoplasms 2022-05-20
DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended

2023-505690-33-00 Metastatic Breast Cancer 2022-03-11
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants wit… Ended

2023-506699-29-00 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r 2022-03-03
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours Ended

2024-511071-16-00 Solid Tumours 2022-02-10
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL Ended

2024-511489-35-00 Relapsed/refractory Non Hodgkin Lymphoma 2022-01-24
Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended

2024-514907-32-00 non-metastatic soft tissue sarcoma 2022-01-21
A Proof of Concept Study Non-Randomized, Single-Center Pilot Trial Assessing The Safety/Efficacy Of Dual Targeting Of Peripheral And Central… Ended

2024-518128-66-00 patients with cPRA or TGI ≥ 95% on the deceased donor k 2022-01-11
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody… Ended

2023-506117-22-00 Acute Myeloid Leukemia and Myelodysplastic Syndromes 2022-01-05
Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1) Ended

2024-514168-15-00 N+M0 prostate cancer 2021-12-17